SCHEMBL1175809

SCHEMBL1175809

CCc1cc(-c2nnc(-c3cc(C)cc(CN(C)CC)c3)o2)cc(C)c1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 13/20 0.48
S1PR3 Q99500 12/20 0.48
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
MYC P01106 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ACHE P22303 3/20 0.36
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10005028 0.82 S1PR1 (0.43) S1PR1S1PR3MEN1KMT2AMYC
SCHEMBL1176353 0.81 S1PR1 (0.60) S1PR1S1PR3
SCHEMBL1174943 0.79 S1PR1 (0.44) S1PR1S1PR3ALDH1A1
SCHEMBL3277355 0.78 S1PR1 (0.59) S1PR1S1PR3MEN1KMT2AMYC
SCHEMBL1175672 0.76 S1PR1 (0.81) S1PR1S1PR3
SCHEMBL1175670 0.76 S1PR1 (0.81) S1PR1S1PR3
SCHEMBL2545632 0.75 S1PR1 (0.47) S1PR1S1PR3MYCALDH1A1KDM4E
SCHEMBL27752453 0.75 S1PR1 (0.44) S1PR1S1PR3MYCALDH1A1KDM4E
SCHEMBL1175420 0.71 S1PR1 (0.63) S1PR1S1PR3
SCHEMBL1188343 0.71 ALDH1A1 (0.40) S1PR1S1PR3MEN1KMT2AMYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410151-B2 Aminomethyl benzene derivatives ACTELION PHARMACEUTICALS LTD (CH) 2013-04-02 US disclosed
EP-2262782-B1 NOVEL AMINOMETHYL BENZENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-07-04 EP disclosed
US-20110028449-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-03 US disclosed
EP-2262782-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109904-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028449-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES CD47, BRD4, BRD3 S1PR1 2558/4885S1PR3 2590/4885MEN1 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.